Second edition

22.qxd 3/10/08 10:01 AM Page 699
Lazar RB, Ho SU, Melen O et al. Multifocal central nervous system
damage caused by toluene abuse. Neurology 1983;
33:1337–40.
Lechevalier B, Anderson JC, Morin P. Hemispheric disconnection
syndrome with a ‘crossed avoiding’ reaction in a case of
Marchiafava–Bignami disease. J Neurol Neurosurg Psychiatry
1977; 40:483–97.
Lee K, Moller L, Hardt F et al. Alcohol induced brain damage and
liver damage in young males. Lancet 1979; 2:759–61.
Leong ASV. Marchiafava–Bignami disease in a non-alcoholic
Indian male. Pathology 1979; 11:241–9.
Lerner V, Miodownik C, Kapstan A et al. Vitamin B6 in the
treatment of tardive dyskinesia: a double-blind, placebocontrolled,
crossover study. Am J Psychiatry 2001;
158:1511–14.
Levenson JL. Neuroleptic malignant syndrome after the initiation
of olanzapine. J Clin Psychopharmacol 1999; 19:477–8.
Levin GM, Lazowick AL, Powell HS. Neuroleptic malignant syndrome
with risperidone. J Clin Psychopharmacol 1996; 16:192–3.
Lewis JD, Moritz D, Mellis LP. Long-term toluene abuse. Am J
Psychiatry 1981; 138:368–70.
Lhermitte F, Marteau R, Serdaru M et al. Signs of interhemispheric
disconnection in Marchiafava–Bignami disease. Arch Neurol
1977; 34:254–7.
Libov I, Miodowni C, Bersudsky Y et al. Efficacy of piracetam in
the treatment of tardive dyskinesia in schizophrenic patients:
a randomized, double-blind, placebo-controlled crossover
study. J Clin Psychiatry 2007; 68:1031–7.
Lishman WA. Cerebral disorder in alcoholism: syndromes of
impairment. Brain 1981; 104:373–410.
Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of
vitamin E in the treatment of tardive dyskinesia. J Clin
Psychiatry 1996; 57:167–73.
Lohr JB, Cadet JL, Lohr MA et al. Vitamin E in the treatment of
tardive dyskinesia: the possible involvement of free radical
mechanisms. Schizophr Bull 1988; 14:291–6.
Lu ML, Pan JJ, Teng HW et al. Metoclopramide-induced
supersensitivity psychosis. Ann Pharmacother 2002;
36:1387–90.
Luchins DJ, Freed WJ, Wyatt RJ. The role of cholinergic
supersensitivity in the medical symptoms associated with
withdrawal of antipsychotic drugs. Am J Psychiatry 1980;
137:1395–8.
Lynch MJG. Brain lesions in chronic alcoholism. Arch Pathol 1960;
69:342–53.
Marchiafava E, Bignami A. Sopra un alterazione del corpo callsos
osservata in sogetti alcoolisti. Riv Patol Nerv Mentale 1903;
8:544–9.
Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome.
Presentation of 2 cases and review of the literature. Medicine
2000; 79:201–9.
May EDC, Morris SW, Stewart RM et al. Neuroleptic malignant
syndrome: response to dantrolene sodium. Ann Intern Med
1983; 98:183–4.
Mayer JM, De Liege P, Netter JM et al. Computerized tomography
and nuclear magnetic resonance imaging in Marchiafava–
Bignami disease. J Neuroradiol 1987; 14:152–8.
References 699
Mendhekar DN, Andrade CR. Neuroleptic malignant syndrome
with promethazine. Aust N Z J Psychiatry 2005; 39:310.
Menegon P, Sibon I, Pachia C et al. Marchiafava–Bignami
disease: diffusion-weighted MRI in corpus callosum and
cortical lesions. Neurology 2005; 65:475–7.
Meterissian GB. Risperidone-induced neuroleptic malignant
syndrome: a case report and review. Can J Psychiatry 1996;
41:52–4.
Mettler FA, Crandall A. Neurologic disorders in psychiatric
institutions. J Nerv Ment Dis 1959; 128:148–59.
Miller DD, Sharafuddin MJA, Kathol RG. A case of clozapineinduced
neuroleptic malignant syndrome. J Clin Psychiatry
1991; 52:99–101.
Moncrieff J. Does antipsychotic withdrawal provoke psychosis?
Review of the literature on rapid onset psychosis
(supersensitivity psychosis) and withdrawal-related relapse.
Acta Psychiatr Scand 2006; 114:3–13.
Moore DP. Tardive psychosis. J Ky Med Assoc 1986; 84:351–3.
Morganstern H, Glazer WM. Identifying risk factors for tardive
dyskinesia among the long-term outpatients maintained
with neuroleptic medications. Arch Gen Psychiatry 1993;
50:723–33.
Mueller PS, Vester JW, Fermaglich J. Neuroleptic malignant
syndrome – successful treatment with bromocriptine. JAMA
1983; 249:386–8.
Neuberger KT. The changing neuropathological picture of chronic
alcoholism. Arch Pathol 1957; 63:1–6.
Nimmagadda SR, Ryan DH, Atkin SL. Neuroleptic malignant
syndrome after venlafaxine. Lancet 2000; 354:289–90.
Oberndorfer S, Grisold W, Hinterholzer G et al. Coma with focal
neurological signs caused by Datura stramonium intoxication
in a young man. J Neurol Neurosurg Psychiatry 2002; 73:458–9.
Ondo WG, Hanna PA, Jankovi J. Tetrabenazine treatment for
tardive dyskinesia: assessment by randomized videotape
protocol. Am J Psychiatry 1999; 156:1279–81.
Ossemann M, Sindic CJM, Laterre C. Tetrabenazine as a cause of
neuroleptic malignant syndrome. Mov Disord 1996; 11:95.
Owens DGC, Johnstone EC, Frith CD. Spontaneous involuntary
disorders of movement: their prevalence, severity and
distribution in chronic schizophrenics with and without
treatment with neuroleptics. Arch Gen Psychiatry 1982;
39:452–61.
Ozen ME, Yumru M, Savas HA et al. Neuroleptic malignant
syndrome induced by ziprasidone on the second day of
treatment: a case report. World J Biol Psychiatry 2007;
8:133–4.
Parvin MM, Swartz CM. Dystonic rabbit syndrome from
citalopram. Clin Neuropharmacol 2005; 28:289–91.
Peiris DTS, Kuruppuarachchi KALA, Weeasena LP et al. Neuroleptic
malignant syndrome without fever: a report of three cases.
J Neurol Neurosurg Psychiatry 2000; 69:277–8.
Petti TA, Law W. Abrupt cessation of high-dose imipramine
treatment in children. JAMA 1981; 246:768–9.
Pfefferbaum A, Sullivan EV, Mathalon DH et al. Longitudinal
changes in magnetic resonance imaging brain volumes in
abstinent and relapsed alcoholics. Alcohol Clin Exp Res 1995;
19:1177–91.